# Hemosphere

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hemosphere

- Industry: Medical Devices & Equipment
- Headquarters: Eden Prairie, US
- Website: www.hemosphere.com
- Total disclosed funding: $37M
- Latest round: Series A (Mar 29, 2010)
- Investors on record: 8

## About

Hemosphere Inc. is a medical technology company focused on developing innovative solutions for hemodialysis and interventional procedures, aimed at improving patient outcomes and reducing complications associated with vascular access.Founded in 1998 in Eden Prairie, US, Hemosphere Inc. specializes in medical devices for hemodialysis. The company has gone through strategic developments, including its acquisition by CryoLife Inc. in May 2012 for USD 21.5 mn. The firm has been involved in six funding deals, with the most recent being an Add-on Trade Sale round led by Artivion, Inc. This funding has contributed to the total amount raised, which stands at USD 9.3 mn.Hemosphere Inc. specializes in medical devices and solutions for hemodialysis and interventional procedures. Their flagship product, the HeRO® Graft, is designed for patients requiring long-term hemodialysis access, particularly those with central venous stenosis and complications from failing fistulas or grafts. This fully subcutaneous graft allows for reduced catheter dependency and has demonstrated a 69% lower infection rate compared to conventional catheters. Other products, such as the Centros® and Super HeRO® systems, enhance vascular access and interventional procedures. Their client base includes hospitals and clinics across North America, Europe, the Middle East, and Asia.Hemosphere generates revenue through direct sales of their medical devices to healthcare providers in the hemodialysis sector, primarily through a B2B model. Hospitals and clinics purchase devices like the HeRO Graft and related accessories, facilitated by partnerships with medical distributors and sales representatives. Pricing reflects the advanced technology of the products, enabling healthcare providers to achieve significant cost savings over time, thus ensuring a steady revenue stream.The company plans to utilize funding from its latest deal in May 2012 to support the development of new products designed for advanced hemodialysis applications. Expansion efforts are focused on penetrating new markets in Europe and Asia, expected to ramp up by late 2023. The recent capital infusion will aid in enhancing product offerings and market outreach, fortifying its presence in these regions.

## Funding rounds

- Series A, Mar 29, 2010, $9.3M — Saints Capital, Affinity Capital Management, Cutlass Capital, Ascension Ventures, Mutual Capital Partners, Kaiser Permanente Ventures
- Series D, Feb 20, 2008, $12M — Three Arch Partners, Affinity Capital Management, Sapient Capital, Cutlass Capital, Ascension Ventures
- Series D, Nov 28, 2007, $10M — Three Arch Partners, Affinity Capital Management, Sapient Capital, Cutlass Capital, Ascension Ventures
- Series A, Feb 15, 2004, $5.8M — Three Arch Partners, Sapient Capital, Cutlass Capital

## Investors

- Three Arch Partners (https://capitalatlas.ai/funds/three-arch-partners) — Series A, Series D
- Sapient Capital (https://capitalatlas.ai/funds/sapient-capital) — Series A, Series D
- Cutlass Capital (https://capitalatlas.ai/funds/cutlass-capital) — Series A, Series D
- Affinity Capital Management (https://capitalatlas.ai/funds/affinity-capital-management) — Series D, Series A
- Ascension Ventures (https://capitalatlas.ai/funds/ascension-ventures) — Series D, Series A
- Saints Capital (https://capitalatlas.ai/funds/saints-capital) — Series A
- Mutual Capital Partners (https://capitalatlas.ai/funds/mutual-capital-partners) — Series A
- Kaiser Permanente Ventures (https://capitalatlas.ai/funds/kaiser-permanente-ventures) — Series A